Vaxart, Inc. (VXRT)
USD 0.29
(-12.84%)
USD 0.29
(-12.84%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -82.46 Million USD | 23.47% |
| 2022 | -107.75 Million USD | -52.91% |
| 2021 | -70.47 Million USD | -118.72% |
| 2020 | -32.22 Million USD | -72.81% |
| 2019 | -18.64 Million USD | -3.54% |
| 2018 | -18 Million USD | -44.52% |
| 2017 | -12.46 Million USD | 57.62% |
| 2016 | -29.4 Million USD | -15.75% |
| 2015 | -25.4 Million USD | -32.98% |
| 2014 | -19.1 Million USD | -73.64% |
| 2013 | -11 Million USD | -23.6% |
| 2012 | -8.9 Million USD | -96.42% |
| 2011 | -4.53 Million USD | -616.06% |
| 2010 | 878 Thousand USD | 104.69% |
| 2009 | -18.72 Million USD | 0.06% |
| 2008 | -18.73 Million USD | -139.81% |
| 2007 | 47.06 Million USD | 180.18% |
| 2006 | -58.7 Million USD | 54.3% |
| 2005 | -128.44 Million USD | -154.91% |
| 2004 | -50.39 Million USD | -637.56% |
| 2003 | -6.83 Million USD | -432.46% |
| 2002 | 2.05 Million USD | -98.04% |
| 2001 | 104.68 Million USD | 2301.51% |
| 2000 | 4.35 Million USD | 32.09% |
| 1999 | 3.3 Million USD | 115.14% |
| 1998 | -21.8 Million USD | -94.64% |
| 1997 | -11.2 Million USD | -184.21% |
| 1996 | 13.3 Million USD | 175.57% |
| 1995 | -17.6 Million USD | -322.78% |
| 1994 | 7.9 Million USD | 125.71% |
| 1993 | 3.5 Million USD | 683.33% |
| 1992 | -600 Thousand USD | -127.27% |
| 1991 | 2.2 Million USD | 0.0% |
| 1990 | 2.2 Million USD | 175.0% |
| 1989 | 800 Thousand USD | 300.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -24.41 Million USD | -40.53% |
| 2024 Q2 | -16.46 Million USD | 32.56% |
| 2023 Q3 | -17.4 Million USD | 22.84% |
| 2023 Q1 | -25.14 Million USD | -5.11% |
| 2023 Q2 | -22.55 Million USD | 10.3% |
| 2023 Q4 | -17.37 Million USD | 0.14% |
| 2023 FY | -82.46 Million USD | 23.47% |
| 2022 Q1 | -25.1 Million USD | -20.89% |
| 2022 Q4 | -23.91 Million USD | 18.39% |
| 2022 Q3 | -29.3 Million USD | 0.41% |
| 2022 Q2 | -29.43 Million USD | -17.25% |
| 2022 FY | -107.75 Million USD | -52.91% |
| 2021 Q1 | -16 Million USD | -15.48% |
| 2021 Q2 | -16.11 Million USD | -0.68% |
| 2021 FY | -70.47 Million USD | -118.72% |
| 2021 Q4 | -20.76 Million USD | -18.09% |
| 2021 Q3 | -17.58 Million USD | -9.1% |
| 2020 Q1 | -1.29 Million USD | 79.76% |
| 2020 Q2 | -8.97 Million USD | -592.14% |
| 2020 Q4 | -13.86 Million USD | -71.44% |
| 2020 Q3 | -8.08 Million USD | 9.94% |
| 2020 FY | -32.22 Million USD | -72.81% |
| 2019 Q1 | -1.33 Million USD | 72.68% |
| 2019 Q2 | -5.63 Million USD | -320.99% |
| 2019 Q3 | -5.26 Million USD | 6.69% |
| 2019 Q4 | -6.4 Million USD | -21.84% |
| 2019 FY | -18.64 Million USD | -3.54% |
| 2018 Q4 | -4.9 Million USD | 25.14% |
| 2018 FY | -18 Million USD | -44.52% |
| 2018 Q1 | 1.97 Million USD | 158.09% |
| 2018 Q2 | -8.87 Million USD | -549.16% |
| 2018 Q3 | -6.54 Million USD | 26.19% |
| 2017 FY | -12.46 Million USD | 57.62% |
| 2017 Q3 | -5.3 Million USD | 10.17% |
| 2017 Q4 | -3.4 Million USD | 35.85% |
| 2017 Q2 | -5.9 Million USD | -34.09% |
| 2017 Q1 | -4.4 Million USD | 51.65% |
| 2016 FY | -29.4 Million USD | -15.75% |
| 2016 Q4 | -9.1 Million USD | 9.0% |
| 2016 Q3 | -10 Million USD | -42.86% |
| 2016 Q2 | -7 Million USD | -34.62% |
| 2016 Q1 | -5.2 Million USD | 20.0% |
| 2015 FY | -25.4 Million USD | -32.98% |
| 2015 Q4 | -6.5 Million USD | 1.52% |
| 2015 Q1 | 1.2 Million USD | -81.54% |
| 2015 Q2 | -19.9 Million USD | -1758.33% |
| 2015 Q3 | -6.6 Million USD | 66.83% |
| 2014 Q3 | -6.9 Million USD | 32.35% |
| 2014 Q1 | 3.2 Million USD | 3300.0% |
| 2014 Q4 | 6.5 Million USD | 194.2% |
| 2014 FY | -19.1 Million USD | -73.64% |
| 2014 Q2 | -10.2 Million USD | -418.75% |
| 2013 Q2 | -6.5 Million USD | -3124.19% |
| 2013 FY | -11 Million USD | -23.6% |
| 2013 Q4 | -100 Thousand USD | 97.44% |
| 2013 Q3 | -3.9 Million USD | 40.02% |
| 2013 Q1 | 215 Thousand USD | -95.55% |
| 2012 FY | -8.9 Million USD | -96.42% |
| 2012 Q2 | -2.73 Million USD | -526.83% |
| 2012 Q3 | -4.09 Million USD | -49.65% |
| 2012 Q1 | -436 Thousand USD | 78.09% |
| 2012 Q4 | 4.82 Million USD | 218.07% |
| 2011 Q4 | -1.99 Million USD | -2651.28% |
| 2011 Q1 | 1.98 Million USD | 131.27% |
| 2011 Q2 | -4.59 Million USD | -332.27% |
| 2011 Q3 | 78 Thousand USD | 101.7% |
| 2011 FY | -4.53 Million USD | -616.06% |
| 2010 Q3 | 5.13 Million USD | 250.76% |
| 2010 FY | 878 Thousand USD | 104.69% |
| 2010 Q4 | -6.33 Million USD | -223.29% |
| 2010 Q2 | -3.4 Million USD | -162.15% |
| 2010 Q1 | 5.48 Million USD | 393.69% |
| 2009 FY | -18.72 Million USD | 0.06% |
| 2009 Q1 | -7.04 Million USD | -195.43% |
| 2009 Q4 | 1.11 Million USD | 115.9% |
| 2009 Q2 | -5.8 Million USD | 17.57% |
| 2009 Q3 | -6.98 Million USD | -20.23% |
| 2008 Q4 | -2.38 Million USD | -39.07% |
| 2008 Q3 | -1.71 Million USD | -356.12% |
| 2008 Q2 | -376 Thousand USD | 93.97% |
| 2008 Q1 | -6.24 Million USD | -107.92% |
| 2008 FY | -18.73 Million USD | -139.81% |
| 2007 Q3 | -15.87 Million USD | -232.23% |
| 2007 Q4 | 78.75 Million USD | 596.09% |
| 2007 Q1 | -11.02 Million USD | -176.49% |
| 2007 Q2 | -4.77 Million USD | 56.68% |
| 2007 FY | 47.06 Million USD | 180.18% |
| 2006 Q4 | -3.98 Million USD | 81.71% |
| 2006 FY | -58.7 Million USD | 54.3% |
| 2006 Q3 | -21.81 Million USD | -47.15% |
| 2006 Q2 | -14.82 Million USD | 18.0% |
| 2006 Q1 | -18.07 Million USD | 76.08% |
| 2005 Q2 | -20.93 Million USD | -32.28% |
| 2005 FY | -128.44 Million USD | -154.91% |
| 2005 Q1 | -15.82 Million USD | 7.21% |
| 2005 Q4 | -75.57 Million USD | -368.91% |
| 2005 Q3 | -16.11 Million USD | 22.99% |
| 2004 Q4 | -17.05 Million USD | -56.14% |
| 2004 Q3 | -10.92 Million USD | 37.87% |
| 2004 Q1 | -4.83 Million USD | 26.4% |
| 2004 Q2 | -17.57 Million USD | -263.26% |
| 2004 FY | -50.39 Million USD | -637.56% |
| 2003 FY | -6.83 Million USD | -432.46% |
| 2003 Q4 | -6.57 Million USD | -399.82% |
| 2003 Q3 | 2.19 Million USD | 173.12% |
| 2003 Q2 | -2.99 Million USD | -646.27% |
| 2003 Q1 | 549 Thousand USD | -48.69% |
| 2002 Q4 | 1.07 Million USD | 29.7% |
| 2002 Q1 | -661 Thousand USD | -145.71% |
| 2002 Q2 | 821 Thousand USD | 224.21% |
| 2002 Q3 | 825 Thousand USD | 0.49% |
| 2002 FY | 2.05 Million USD | -98.04% |
| 2001 FY | 104.68 Million USD | 2301.51% |
| 2001 Q4 | 1.44 Million USD | -98.57% |
| 2001 Q3 | 101.03 Million USD | 6569.04% |
| 2001 Q2 | 1.51 Million USD | 121.17% |
| 2001 Q1 | 685 Thousand USD | -76.35% |
| 2000 Q4 | 2.89 Million USD | 675.75% |
| 2000 FY | 4.35 Million USD | 32.09% |
| 2000 Q1 | 677 Thousand USD | -47.92% |
| 2000 Q2 | 1.28 Million USD | 90.1% |
| 2000 Q3 | -503 Thousand USD | -139.08% |
| 1999 FY | 3.3 Million USD | 115.14% |
| 1999 Q4 | 1.3 Million USD | -13.33% |
| 1999 Q3 | 1.5 Million USD | 36.36% |
| 1999 Q1 | -500 Thousand USD | 96.79% |
| 1999 Q2 | 1.1 Million USD | 320.0% |
| 1998 FY | -21.8 Million USD | -94.64% |
| 1998 Q1 | -1.9 Million USD | 71.64% |
| 1998 Q2 | -500 Thousand USD | 73.68% |
| 1998 Q4 | -15.6 Million USD | -310.53% |
| 1998 Q3 | -3.8 Million USD | -660.0% |
| 1997 Q1 | 1.4 Million USD | -86.0% |
| 1997 Q3 | -7.9 Million USD | -495.0% |
| 1997 Q4 | -6.7 Million USD | 15.19% |
| 1997 FY | -11.2 Million USD | -184.21% |
| 1997 Q2 | 2 Million USD | 42.86% |
| 1996 FY | 13.3 Million USD | 175.57% |
| 1996 Q2 | 1.6 Million USD | 220.0% |
| 1996 Q3 | 1.1 Million USD | -31.25% |
| 1996 Q4 | 10 Million USD | 809.09% |
| 1996 Q1 | 500 Thousand USD | 101.82% |
| 1995 Q3 | 3.5 Million USD | 2.94% |
| 1995 Q4 | -27.5 Million USD | -885.71% |
| 1995 Q1 | 3.1 Million USD | 47.62% |
| 1995 Q2 | 3.4 Million USD | 9.68% |
| 1995 FY | -17.6 Million USD | -322.78% |
| 1994 Q2 | 2.1 Million USD | 31.25% |
| 1994 FY | 7.9 Million USD | 125.71% |
| 1994 Q4 | 2.1 Million USD | 0.0% |
| 1994 Q1 | 1.6 Million USD | 23.08% |
| 1994 Q3 | 2.1 Million USD | 0.0% |
| 1993 Q3 | 1 Million USD | 42.86% |
| 1993 Q4 | 1.3 Million USD | 30.0% |
| 1993 Q1 | 400 Thousand USD | 180.0% |
| 1993 Q2 | 700 Thousand USD | 75.0% |
| 1993 FY | 3.5 Million USD | 683.33% |
| 1992 Q1 | 500 Thousand USD | -16.67% |
| 1992 Q4 | -500 Thousand USD | 50.0% |
| 1992 FY | -600 Thousand USD | -127.27% |
| 1992 Q2 | 400 Thousand USD | -20.0% |
| 1992 Q3 | -1 Million USD | -350.0% |
| 1991 Q4 | 600 Thousand USD | 20.0% |
| 1991 FY | 2.2 Million USD | 0.0% |
| 1991 Q1 | 500 Thousand USD | -16.67% |
| 1991 Q2 | 600 Thousand USD | 20.0% |
| 1991 Q3 | 500 Thousand USD | -16.67% |
| 1990 FY | 2.2 Million USD | 175.0% |
| 1990 Q4 | 600 Thousand USD | 0.0% |
| 1990 Q3 | 600 Thousand USD | 20.0% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 66.67% |
| 1989 Q4 | 300 Thousand USD | -25.0% |
| 1989 FY | 800 Thousand USD | 300.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q3 | 400 Thousand USD | 100.0% |
| 1989 Q2 | 200 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 43.671% |
| Alkermes plc | 355.75 Million USD | 123.18% |
| Agenus Inc. | -245.76 Million USD | 66.445% |
| Aptorum Group Limited | -2.82 Million USD | -2819.48% |
| Ardelyx, Inc. | -66.06 Million USD | -24.82% |
| Dyadic International, Inc. | -6.79 Million USD | -1113.531% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -8710.363% |
| Lantern Pharma Inc. | -15.96 Million USD | -416.648% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | -333.368% |
| Novavax, Inc. | -545.06 Million USD | 84.871% |
| Janux Therapeutics, Inc. | -58.29 Million USD | -41.466% |
| Pyxis Oncology, Inc. | -73.79 Million USD | -11.756% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | -344.649% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -725.806% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | -39.812% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 77.929% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -238.814% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | -120.849% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 49.892% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | -12.431% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -306.412% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -32.463% |
| Clearside Biomedical, Inc. | -32.48 Million USD | -153.856% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 37.759% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 81.268% |
| AlloVir, Inc. | -190.41 Million USD | 56.693% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 59.827% |
| VYNE Therapeutics Inc. | -28.45 Million USD | -189.839% |
| Bicycle Therapeutics plc | -180.66 Million USD | 54.354% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 53.944% |
| ChromaDex Corporation | -4.93 Million USD | -1570.008% |
| Chimerix, Inc. | -82.09 Million USD | -0.451% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -84.885% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 19.207% |
| CRISPR Therapeutics AG | -153.61 Million USD | 46.315% |
| Precision BioSciences, Inc. | -61.31 Million USD | -34.485% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 48.757% |
| Fortress Biotech, Inc. | -60.63 Million USD | -35.998% |
| Fortress Biotech, Inc. | -60.63 Million USD | -35.998% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | -1.085% |
| ImmuCell Corporation | -5.77 Million USD | -1328.065% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 26.997% |
| Immix Biopharma, Inc. | -15.42 Million USD | -434.583% |
| Incyte Corporation | 597.59 Million USD | 113.799% |
| Innoviva, Inc. | 179.72 Million USD | 145.885% |
| IO Biotech, Inc. | -86.08 Million USD | 4.203% |
| Jaguar Health, Inc. | -41.3 Million USD | -99.673% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 46.098% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 258.118% |
| ContextLogic Inc. | -317 Million USD | 73.986% |
| MiMedx Group, Inc. | 67.43 Million USD | 222.281% |
| MEI Pharma, Inc. | 17.77 Million USD | 563.86% |
| NextCure, Inc. | -62.72 Million USD | -31.475% |
| Onconetix, Inc. | -37.4 Million USD | -120.438% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | -108.883% |
| Opthea Limited | -220.24 Million USD | 62.557% |
| Psyence Biomedical Ltd. | -51.15 Million USD | -61.193% |
| Vaxcyte, Inc. | -402.26 Million USD | 79.5% |
| PDS Biotechnology Corporation | -42.94 Million USD | -92.037% |
| Precigen, Inc. | -95.9 Million USD | 14.013% |
| Pharming Group N.V. | -10.54 Million USD | -681.807% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 59.093% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | -236.002% |
| PureTech Health plc | -65.69 Million USD | -25.523% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | -228.664% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 61.142% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -238.814% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 68.016% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | -202.757% |
| Acelyrin, Inc. | -381.64 Million USD | 78.392% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -657374.593% |
| Summit Therapeutics Inc. | -614.92 Million USD | 86.589% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | -141.826% |
| Senti Biosciences, Inc. | -92.91 Million USD | 11.251% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 21.236% |
| Elevation Oncology, Inc. | -45.7 Million USD | -80.433% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | -134.676% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -530.859% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -1133.583% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | -180.856% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -870.062% |
| Wave Life Sciences Ltd. | -57.51 Million USD | -43.385% |
| Seer, Inc. | -86.27 Million USD | 4.418% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | -23.091% |
| Aadi Bioscience, Inc. | -65.76 Million USD | -25.393% |
| ESSA Pharma Inc. | -26.58 Million USD | -210.225% |
| GlycoMimetics, Inc. | -36.89 Million USD | -123.486% |
| GT Biopharma, Inc. | -7.59 Million USD | -985.494% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 65.833% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | -58.816% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 215.481% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | -51.529% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | -67.885% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -728.982% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 85.604% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -2198.356% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -61.512% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 66.422% |
| Aptose Biosciences Inc. | -51.2 Million USD | -61.042% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 16.107% |
| Soligenix, Inc. | -6.14 Million USD | -1242.919% |
| Century Therapeutics, Inc. | -136.67 Million USD | 39.663% |
| Kura Oncology, Inc. | -152.63 Million USD | 45.971% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 7.569% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -682.549% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 14683.444% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -14392.97% |
| Autolus Therapeutics plc | -208.38 Million USD | 60.426% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | -14.697% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | -16.484% |
| Eterna Therapeutics Inc. | -21.66 Million USD | -280.584% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 63.39% |
| GRI Bio, Inc. | -13.03 Million USD | -532.546% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -1894.52% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 33.541% |
| IGM Biosciences, Inc. | -246.41 Million USD | 66.534% |
| INmune Bio, Inc. | -30 Million USD | -174.81% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 25.411% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -95.443% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -416.644% |
| Entero Therapeutics, Inc. | -15.79 Million USD | -422.096% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | -38.167% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 18.486% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 70.135% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 65.335% |
| Verastem, Inc. | -87.36 Million USD | 5.611% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -52.183% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 48.886% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 29.31% |
| Histogen Inc. | -10.62 Million USD | -676.433% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | -477.213% |
| Surrozen, Inc. | -43.04 Million USD | -91.592% |
| Organovo Holdings, Inc. | -14.67 Million USD | -462.095% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -1521.084% |
| Ovid Therapeutics Inc. | -52.33 Million USD | -57.559% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -226.426% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | -206.129% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -886.767% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 45.418% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | -68.55% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | -177.426% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -691.585% |
| Apollomics, Inc. | -172.6 Million USD | 52.222% |
| Amarin Corporation plc | -59.11 Million USD | -39.506% |
| Mesoblast Limited | -87.95 Million USD | 6.243% |
| Turnstone Biologics Corp. | -55.2 Million USD | -49.393% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 43.887% |
| Synaptogenix, Inc. | -6.03 Million USD | -1265.653% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | -408.792% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | -5.697% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1621.081% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -881.47% |
| Exelixis, Inc. | 207.76 Million USD | 139.691% |
| Better Therapeutics, Inc. | -39.76 Million USD | -107.407% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 42.712% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 84.4% |
| NLS Pharmaceutics AG | -12.17 Million USD | -577.496% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -957.964% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -168.188% |
| Gritstone bio, Inc. | -138.49 Million USD | 40.454% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -27.922% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1961.651% |
| Avid Bioservices, Inc. | -140.75 Million USD | 41.412% |
| Insmed Incorporated | -749.56 Million USD | 88.998% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | -442.908% |
| MediWound Ltd. | -6.71 Million USD | -1127.889% |
| OmniAb, Inc. | -50.61 Million USD | -62.913% |
| Alector, Inc. | -130.39 Million USD | 36.756% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 27.487% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | -59.055% |
| Zai Lab Limited | -334.62 Million USD | 75.356% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 74.547% |
| Aura Biosciences, Inc. | -76.4 Million USD | -7.927% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 64.853% |
| Immunic, Inc. | -93.61 Million USD | 11.908% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 39.316% |
| Veracyte, Inc. | -74.4 Million USD | -10.834% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -974.386% |
| FibroGen, Inc. | -284.23 Million USD | 70.987% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -214.368% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -1077.753% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | -337.882% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 119.879% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | -265.617% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 267.37% |
| TG Therapeutics, Inc. | 12.67 Million USD | 750.765% |
| Galecto, Inc. | -38.34 Million USD | -115.038% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -337.109% |
| Fortrea Holdings Inc. | -3.4 Million USD | -2325.441% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 34.884% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | -373.637% |
| XBiotech Inc. | -24.55 Million USD | -235.811% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -27.922% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | -31.565% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 16.216% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | -284.865% |
| Theravance Biopharma, Inc. | -55.19 Million USD | -49.412% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 86.406% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | -20.819% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -144743.152% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 63.598% |
| Gain Therapeutics, Inc. | -22.26 Million USD | -270.338% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 62.466% |
| NexImmune, Inc. | -32.34 Million USD | -154.959% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -1459.895% |
| Marker Therapeutics, Inc. | -14.04 Million USD | -487.111% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.086% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | -240.469% |
| Scopus BioPharma Inc. | -11.6 Million USD | -610.303% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 29.395% |
| Ainos, Inc. | -13.77 Million USD | -498.85% |
| Pluri Inc. | -20.88 Million USD | -294.796% |
| Prothena Corporation plc | -147.02 Million USD | 43.912% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 27.58% |
| Celularity Inc. | -196.29 Million USD | 57.989% |
| Rallybio Corporation | -74.56 Million USD | -10.596% |
| Cue Biopharma, Inc. | -50.73 Million USD | -62.547% |
| MeiraGTx Holdings plc | -84.02 Million USD | 1.859% |
| Omeros Corporation | -117.81 Million USD | 30.003% |
| Humacyte, Inc. | -110.77 Million USD | 25.557% |
| Immunocore Holdings plc | -55.28 Million USD | -49.158% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | -358.546% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | -259.622% |
| Blueprint Medicines Corporation | -506.98 Million USD | 83.734% |
| CalciMedica, Inc. | -34.35 Million USD | -140.024% |
| Cabaletta Bio, Inc. | -67.67 Million USD | -21.854% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 41.682% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 50.259% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 70.887% |
| Pulmatrix, Inc. | -14.12 Million USD | -483.988% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | -134.309% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 0.209% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 82.862% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 21.365% |
| Cytokinetics, Incorporated | -526.24 Million USD | 84.33% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -128.657% |
| Nutriband Inc. | -5.48 Million USD | -1403.378% |
| Protara Therapeutics, Inc. | -40.42 Million USD | -104.02% |
| Vor Biopharma Inc. | -117.86 Million USD | 30.033% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 101.896% |
| Evogene Ltd. | -23.87 Million USD | -245.345% |
| ProKidney Corp. | -35.46 Million USD | -132.505% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 31.143% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -951.127% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 87.179% |
| CorMedix Inc. | -46.33 Million USD | -77.959% |
| BioLineRx Ltd. | -60.61 Million USD | -36.049% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 18.949% |
| Galectin Therapeutics Inc. | -41.06 Million USD | -100.811% |
| Atai Life Sciences N.V. | -40.22 Million USD | -105.014% |
| Renovaro Biosciences Inc. | -80.65 Million USD | -2.25% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | -9.195% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 71.777% |
| Sagimet Biosciences Inc. | -27.87 Million USD | -195.828% |
| MediciNova, Inc. | -8.57 Million USD | -862.082% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 33.106% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -884.441% |
| GeoVax Labs, Inc. | -25.96 Million USD | -217.579% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 65.53% |
| Biomea Fusion, Inc. | -117.25 Million USD | 29.67% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 86.839% |
| Mereo BioPharma Group plc | -29.46 Million USD | -179.865% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 46.158% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 60.611% |
| Absci Corporation | -110.56 Million USD | 25.416% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -173.516% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 18.22% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 65.048% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 685.523% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 57.264% |
| Allakos Inc. | -185.7 Million USD | 55.593% |
| Imunon, Inc. | -19.51 Million USD | -322.573% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 15.277% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 177.695% |
| BioAtla, Inc. | -123.46 Million USD | 33.206% |
| NLS Pharmaceutics AG | -12.17 Million USD | -577.496% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -412.906% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 74.802% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | -123.186% |
| XOMA Corporation | -40.83 Million USD | -101.967% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 19.049% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 30.417% |
| aTyr Pharma, Inc. | -50.38 Million USD | -63.657% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 5.947% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 45.661% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 65.312% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | -134.816% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -919.1% |
| Akari Therapeutics, Plc | -10 Million USD | -723.991% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -122387.932% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 129.285% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -1137.303% |
| UroGen Pharma Ltd. | -102.24 Million USD | 19.345% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 22.781% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -960.345% |
| Orgenesis Inc. | -55.36 Million USD | -48.959% |
| Entera Bio Ltd. | -8.88 Million USD | -827.72% |
| GH Research PLC | -35.58 Million USD | -131.728% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | -295.705% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | -6.56% |
| Xencor, Inc. | -126.08 Million USD | 34.597% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -2089.897% |
| Replimune Group, Inc. | -215.79 Million USD | 61.785% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | -287.769% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 3386.768% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -1137.303% |
| Portage Biotech Inc. | -75.33 Million USD | -9.459% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -884.441% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 14.681% |
| OncoCyte Corporation | -27.78 Million USD | -196.84% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -514.621% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -641.49% |
| Purple Biotech Ltd. | -19.88 Million USD | -314.814% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -1074.882% |
| scPharmaceuticals Inc. | -54.81 Million USD | -50.456% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | -371.063% |
| HilleVax, Inc. | -123.56 Million USD | 33.262% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -715.92% |
| Tharimmune, Inc. | -9.31 Million USD | -784.904% |
| Genprex, Inc. | -30.86 Million USD | -167.219% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 65.046% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | -174.025% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -4527.666% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -1457.114% |
| OKYO Pharma Limited | -16.82 Thousand USD | -490020.33% |
| Savara Inc. | -54.69 Million USD | -50.764% |
| Curis, Inc. | -47.41 Million USD | -73.929% |
| Daré Bioscience, Inc. | -30.16 Million USD | -173.412% |
| Carmell Therapeutics Corporation | -15.44 Million USD | -433.924% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -1380.786% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | -176.589% |
| BeiGene, Ltd. | -881.7 Million USD | 90.647% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -287.269% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 81.102% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | -4.446% |
| Erasca, Inc. | -125.04 Million USD | 34.05% |
| bluebird bio, Inc. | -211.91 Million USD | 61.085% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -1549.136% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 149.19% |
| DBV Technologies S.A. | -72.72 Million USD | -13.391% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -1549.136% |
| Moderna, Inc. | -4.71 Billion USD | 98.251% |
| Vincerx Pharma, Inc. | -40.15 Million USD | -105.356% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -1348.279% |
| Molecular Templates, Inc. | -8.12 Million USD | -915.079% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | -36.559% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 25.973% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 39.074% |
| Spruce Biosciences, Inc. | -47.91 Million USD | -72.092% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 41.692% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 57.141% |
| MacroGenics, Inc. | -9.05 Million USD | -810.411% |
| RenovoRx, Inc. | -10.23 Million USD | -705.952% |
| Adicet Bio, Inc. | -142.65 Million USD | 42.194% |
| Prime Medicine, Inc. | -198.13 Million USD | 58.379% |
| Aditxt, Inc. | -32.38 Million USD | -154.672% |
| Adagene Inc. | -18.94 Million USD | -335.255% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1027.846% |
| Quantum-Si incorporated | -95.96 Million USD | 14.063% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 30.719% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -465.69% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 162.318% |
| SciSparc Ltd. | -5.12 Million USD | -1510.016% |
| Vericel Corporation | -3.18 Million USD | -2491.609% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -68475.681% |
| Minerva Neurosciences, Inc. | -30 Million USD | -174.834% |
| Generation Bio Co. | -126.61 Million USD | 34.868% |
| Astria Therapeutics, Inc. | -72.89 Million USD | -13.135% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | -0.028% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 68.542% |
| Invivyd, Inc. | -198.64 Million USD | 58.486% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 75.886% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -849.339% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 461.593% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -735.173% |
| 2seventy bio, Inc. | -217.57 Million USD | 62.097% |
| ADMA Biologics, Inc. | -28.23 Million USD | -192.025% |
| Clene Inc. | -49.5 Million USD | -66.582% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | -270.005% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | -66.818% |
| GeoVax Labs, Inc. | -25.96 Million USD | -217.579% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 74.863% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | -153.404% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 462.962% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 16.526% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | -10.315% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 48.717% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 86.592% |
| Evaxion Biotech A/S | -22.12 Million USD | -272.723% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | -2.142% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 58.782% |
| Trevena, Inc. | -40.28 Million USD | -104.684% |
| Surrozen, Inc. | -43.04 Million USD | -91.592% |
| Tyra Biosciences, Inc. | -69.13 Million USD | -19.283% |
| Cingulate Inc. | -23.53 Million USD | -250.394% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -1093.07% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -106.887% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -969.492% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 8.586% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | -34.558% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | -38.59% |
| Clearmind Medicine Inc. | -11.95 Million USD | -589.793% |
| Kronos Bio, Inc. | -112.67 Million USD | 26.81% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | -19.174% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -3251379.558% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 3.993% |
| Statera Biopharma, Inc. | -174.4 Million USD | 52.717% |
| ImmunityBio, Inc. | -583.19 Million USD | 85.86% |
| Korro Bio, Inc. | -81.17 Million USD | -1.593% |
| Kineta, Inc. | -14.09 Million USD | -484.9% |
| BioVie Inc. | -32.12 Million USD | -156.736% |
| Codexis, Inc. | -76.24 Million USD | -8.165% |
| Celularity Inc. | -196.29 Million USD | 57.989% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 61.56% |
| Celcuity Inc. | -63.77 Million USD | -29.298% |
| Virax Biolabs Group Limited | -6.73 Million USD | -1124.691% |
| Cibus, Inc. | -267.62 Million USD | 69.187% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | -104.496% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -130.278% |
| IN8bio, Inc. | -30 Million USD | -174.819% |
| Kodiak Sciences Inc. | -260.49 Million USD | 68.342% |
| Annexon, Inc. | -134.23 Million USD | 38.568% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 29.616% |
| Assembly Biosciences, Inc. | -61.22 Million USD | -34.685% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | -161.428% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 77.486% |
| Eyenovia, Inc. | -27.26 Million USD | -202.501% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 481.942% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -15314.019% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | -7.933% |
| Arcellx, Inc. | -70.69 Million USD | -16.657% |
| Cardiff Oncology, Inc. | -41.44 Million USD | -98.994% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 38.374% |
| Regulus Therapeutics Inc. | -30.03 Million USD | -174.545% |
| Moolec Science SA | -51.78 Million USD | -59.233% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | -57.463% |
| Geron Corporation | -184.12 Million USD | 55.213% |
| LAVA Therapeutics N.V. | -41.97 Million USD | -96.467% |
| Royalty Pharma plc | 1.13 Billion USD | 107.267% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 39.344% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -827.427% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | -288.194% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 51.963% |
| Humacyte, Inc. | -110.77 Million USD | 25.557% |
| Structure Therapeutics Inc. | -89.62 Million USD | 7.984% |
| 89bio, Inc. | -142.18 Million USD | 42.003% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | -19.584% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -694.69% |
| Genelux Corporation | -28.29 Million USD | -191.427% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | -183.726% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 53.441% |
| Notable Labs, Ltd. | -11.26 Million USD | -632.111% |
| Liquidia Corporation | -78.5 Million USD | -5.048% |
| Mustang Bio, Inc. | -51.6 Million USD | -59.81% |
| Immunovant, Inc. | -259.33 Million USD | 68.201% |
| Quantum-Si incorporated | -95.96 Million USD | 14.063% |
| Arbutus Biopharma Corporation | -72.84 Million USD | -13.2% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | -325.494% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 14.09% |
| Acasti Pharma Inc. | -12.85 Million USD | -541.601% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | -267.199% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -416.644% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 54.787% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -1817.114% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -561.307% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | -179.628% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | -111.514% |
| PepGen Inc. | -78.62 Million USD | -4.883% |
| Moleculin Biotech, Inc. | -29.76 Million USD | -177.016% |
| United Therapeutics Corporation | 984.8 Million USD | 108.374% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | -270.463% |
| Solid Biosciences Inc. | -96.01 Million USD | 14.112% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1621.081% |
| Immuneering Corporation | -53.47 Million USD | -54.222% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -1521.084% |
| Silo Pharma, Inc. | -3.7 Million USD | -2128.372% |
| Belite Bio, Inc | -31.63 Million USD | -160.701% |
| XOMA Corporation | -40.83 Million USD | -101.967% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | -51.688% |
| Bionomics Limited | -15.49 Billion USD | 99.468% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 1.81% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -182.831% |
| uniQure N.V. | -308.47 Million USD | 73.267% |
| Cassava Sciences, Inc. | -97.21 Million USD | 15.174% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1027.846% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 33.189% |
| Forte Biosciences, Inc. | -31.47 Million USD | -161.993% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -905.462% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | -183.697% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -15314.019% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -214.368% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | -400.243% |
| Altimmune, Inc. | -88.44 Million USD | 6.763% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 45.598% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -182.831% |
| Compugen Ltd. | -18.75 Million USD | -339.72% |
| Peak Bio, Inc. | -1259.26 USD | -6548587.324% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | -79.081% |
| Benitec Biopharma Inc. | -21.75 Million USD | -279.132% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 75.659% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 0.589% |
| Zura Bio Limited | -60.36 Million USD | -36.622% |
| PolyPid Ltd. | -23.86 Million USD | -245.548% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | -424.186% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 0.589% |
| Instil Bio, Inc. | -156.08 Million USD | 47.167% |
| argenx SE | -295.05 Million USD | 72.051% |
| Immunome, Inc. | -106.8 Million USD | 22.79% |
| Compass Therapeutics, Inc. | -42.49 Million USD | -94.063% |
| Verona Pharma plc | -54.36 Million USD | -51.677% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 17.466% |
| Shattuck Labs, Inc. | -87.29 Million USD | 5.536% |
| CervoMed Inc. | -2.17 Million USD | -3696.953% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 33.843% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -519.293% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | -89.335% |
| Moolec Science SA | -51.78 Million USD | -59.233% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -476804.277% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 38.968% |
| AnaptysBio, Inc. | -163.61 Million USD | 49.599% |
| Design Therapeutics, Inc. | -66.86 Million USD | -23.336% |
| Leap Therapeutics, Inc. | -81.41 Million USD | -1.291% |
| NeurAxis, Inc. | -14.62 Million USD | -463.798% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | -117.689% |
| Lumos Pharma, Inc. | -34.03 Million USD | -142.302% |
| Achilles Therapeutics plc | -69.66 Million USD | -18.374% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 17.466% |
| 180 Life Sciences Corp. | -19.93 Million USD | -313.667% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 2840.803% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -3251379.558% |
| Nutriband Inc. | -5.48 Million USD | -1403.378% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 18.106% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | -69.657% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | -6.971% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | -142.758% |
| MoonLake Immunotherapeutics | -36 Million USD | -129.023% |
| Palisade Bio, Inc. | -12.3 Million USD | -570.447% |
| Tourmaline Bio, Inc. | -42.12 Million USD | -95.767% |
| Beam Therapeutics Inc. | -132.52 Million USD | 37.775% |
| Neurogene Inc. | -36.31 Million USD | -127.07% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 49.536% |
| AEON Biopharma, Inc. | -52.55 Million USD | -56.909% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 15.978% |
| Sesen Bio, Inc. | -19.88 Million USD | -314.73% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | -15.2% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -558.987% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 81.428% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 26.084% |
| Athira Pharma, Inc. | -117.67 Million USD | 29.92% |
| Vaccinex, Inc. | -20.25 Million USD | -307.214% |
| HCW Biologics Inc. | -24.99 Million USD | -229.936% |
| XOMA Corporation | -40.83 Million USD | -101.967% |
| Nektar Therapeutics | -276.05 Million USD | 70.127% |
| Arvinas, Inc. | -367.3 Million USD | 77.548% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -122387.932% |
| Merus N.V. | -154.93 Million USD | 46.776% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 15.358% |
| Quince Therapeutics, Inc. | -31.38 Million USD | -162.753% |
| Rezolute, Inc. | -68.45 Million USD | -20.459% |
| Clene Inc. | -49.5 Million USD | -66.582% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -434.672% |
| BeyondSpring Inc. | -21.02 Million USD | -292.205% |
| Synlogic, Inc. | -57.28 Million USD | -43.963% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -592.925% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -661.731% |
| Peak Bio, Inc. | -1259.26 USD | -6548587.324% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | -120.683% |
| Krystal Biotech, Inc. | 10.93 Million USD | 854.345% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 42.372% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 74.634% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -1685.357% |
| MannKind Corporation | -11.93 Million USD | -590.777% |
| Ikena Oncology, Inc. | -68.16 Million USD | -20.977% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | -292.41% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 11.264% |
| Gossamer Bio, Inc. | -179.81 Million USD | 54.139% |
| CohBar, Inc. | -11.96 Million USD | -589.385% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | -219.781% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -173.516% |
| Legend Biotech Corporation | -518.25 Million USD | 84.088% |
| Mural Oncology plc | -207.44 Million USD | 60.248% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 33.558% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -350.882% |
| Disc Medicine, Inc. | -76.42 Million USD | -7.898% |
| Champions Oncology, Inc. | -7.27 Million USD | -1033.384% |
| REGENXBIO Inc. | -263.49 Million USD | 68.703% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -677.013% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -73.592% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | -117.107% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 17.669% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 24807.652% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | -119.658% |
| Cellectis S.A. | -101.05 Million USD | 18.399% |
| Longeveron Inc. | -21.41 Million USD | -285.117% |
| Repare Therapeutics Inc. | -93.79 Million USD | 12.08% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 84.614% |
| Inozyme Pharma, Inc. | -71.16 Million USD | -15.872% |
| Revolution Medicines, Inc. | -436.36 Million USD | 81.102% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -1154.984% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | -167.535% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | -18.94% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | -27.394% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -740.536% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 102.278% |
| Denali Therapeutics Inc. | -145.22 Million USD | 43.215% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -68475.681% |
| Veru Inc. | -93.15 Million USD | 11.473% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | -205.098% |
| Cingulate Inc. | -23.53 Million USD | -250.394% |
| Passage Bio, Inc. | -102.06 Million USD | 19.201% |
| Context Therapeutics Inc. | -23.96 Million USD | -244.117% |
| Exicure, Inc. | -16.91 Million USD | -387.555% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 56.349% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | -118.369% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -1167.264% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 55.347% |
| Nuvalent, Inc. | -126.21 Million USD | 34.665% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -684.212% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 5.081% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | -169.988% |
| OmniAb, Inc. | -50.61 Million USD | -62.913% |
| Anew Medical, Inc. | 1.34 Million USD | 6226.103% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | -413.961% |
| Lipocine Inc. | -16.35 Million USD | -404.309% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | -24.206% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | -29.509% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -95.443% |
| G1 Therapeutics, Inc. | -47.96 Million USD | -71.92% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | -315.839% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 84.771% |
| Ocugen, Inc. | -63.07 Million USD | -30.735% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 13.858% |
| Q32 Bio Inc. | -112.96 Million USD | 26.997% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | -379.671% |
| Alumis Inc. Common Stock | -154.99 Million USD | 46.794% |
| Equillium, Inc. | -13.33 Million USD | -518.41% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | -36.608% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -932.382% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | -337.452% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -39.577% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 27.995% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -348.717% |
| Dominari Holdings Inc. | -22.88 Million USD | -260.392% |
| Edesa Biotech, Inc. | -8.37 Million USD | -884.726% |
| vTv Therapeutics Inc. | -20.25 Million USD | -307.235% |
| Bio-Techne Corporation | 168.1 Million USD | 149.056% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 76.578% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 163.999% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 32.313% |
| Candel Therapeutics, Inc. | -37.93 Million USD | -117.362% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 26.79% |
| Nkarta, Inc. | -117.5 Million USD | 29.818% |
| BioCardia, Inc. | -11.57 Million USD | -612.687% |
| Iterum Therapeutics plc | -38.37 Million USD | -114.915% |